Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte supplement used to treat or prevent hypokalemia. It is available in various formulations, including oral tablets, capsules, liquids, and intravenous solutions. ## Primary Indications * Treatment and prevention of hypokalemia. * Maintenance of potassium levels in patients prone to hypokalemia due to diuretic use, vomiting, diarrhea, or certain medical conditions. ## Adult Dosing * **Oral:** * **Prevention of Hypokalemia:** Typically 20 mEq (10 mmol) per day, divided into 1-2 doses. * **Treatment of Hypokalemia:** Doses vary widely based on severity, ranging from 40 mEq (20 mmol) to 100 mEq (50 mmol) per day, divided into 2-4 doses. The maximum daily oral dose is generally considered to be 200 mEq (100 mmol). * **Maximum single oral dose:** 40 mEq (20 mmol). * **Maximum infusion rate (IV):** Typically 10 mEq/hour (5 mmol/hour) peripherally, and up to 20 mEq/hour (10 mmol/hour) centrally for severe hypokalemia with continuous ECG monitoring. Rates exceeding 10 mEq/hour should only be administered in an ICU setting. * **Maximum concentration (IV):** * Peripheral IV: 40 mEq/L (20 mmol/L). * Central IV: 80-120 mEq/L (40-60 mmol/L), but higher concentrations (up to 200 mEq/L or 100 mmol/L) may be used in life-threatening situations with extreme caution and central access. * *Note: Specific dosing protocols may vary by institution, especially for IV administration.* ## Pediatric Dosing * **Oral:** * **Prevention of Hypokalemia:** 1-2 mEq/kg/day (1-2 mmol/kg/day), not to exceed adult maximums. * **Treatment of Hypokalemia:** 2-5 mEq/kg/day (2-5 mmol/kg/day), divided into 2-4 doses, not to exceed adult maximums. * **Intravenous:** * **General maintenance:** 20-40 mEq/day (20-40 mmol/day) for children, or 1-2 mEq/kg/day (1-2 mmol/kg/day). * **Treatment of Hypokalemia:** Doses should be individualized based on serum potassium levels and clinical status. Typically initiated at 0.5-1 mEq/kg (0.5-1 mmol) per dose, administered over 1-3 hours. * **Maximum infusion rate (IV):** 0.5-1 mEq/kg/hour (0.5-1 mmol/kg/hour), not to exceed 20 mEq/hour (10 mmol/hour) without continuous ECG monitoring. * **Maximum concentration (IV):** Generally limited to 40 mEq/L (20 mmol/L) in peripheral lines and 80 mEq/L (40 mmol/L) in central lines. Higher concentrations may be used in critical care settings with caution. * *Note: Pediatric IV potassium administration requires careful calculation and monitoring due to the risk of cardiac arrhythmias.* ## Dose Adjustments * **Renal Impairment:** Dose must be reduced, and serum potassium closely monitored. In severe renal impairment, potassium administration may be contraindicated. * **Adrenal Insufficiency:** Increased sensitivity to potassium; dose reduction may be necessary. ## Contraindications * Hyperkalemia. * Conditions that may cause hyperkalemia (e.g., severe renal impairment, untreated Addison's disease, acute dehydration, extensive tissue injury). * Certain medications that can cause hyperkalemia (see Drug Interactions). ## Adverse Effects * **Common:** Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain). Oral formulations can cause gastrointestinal irritation, ulceration, or bleeding. * **Serious:** Hyperkalemia, cardiac arrhythmias (including cardiac arrest), hypotension (especially with rapid IV administration). ## Key Drug Interactions * **ACE Inhibitors and ARBs:** Increase risk of hyperkalemia. * **Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene):** Increase risk of hyperkalemia. * **NSAIDs:** May reduce potassium excretion, increasing risk of hyperkalemia. * **Heparin:** May impair potassium excretion, increasing risk of hyperkalemia. * **Digoxin:** Hyperkalemia can increase digoxin toxicity; hypokalemia can increase the risk of digoxin toxicity. ## Monitoring * **Serum potassium levels:** Monitor frequently, especially during initiation of therapy, dose changes, and in patients with impaired renal function or concurrent interacting medications. * **Renal function:** Assess baseline and monitor periodically. * **ECG:** Essential for patients receiving rapid IV potassium, particularly at concentrations >10 mEq/hour or in those with cardiac disease. * **Signs and symptoms of hyperkalemia:** Muscle weakness, fatigue, bradycardia, arrhythmias, flaccid paralysis. * **Signs and symptoms of hypokalemia:** Muscle cramps, fatigue, weakness, constipation, arrhythmias. ## Clinical Pearls * Always dilute oral potassium chloride solutions with water, juice, or other liquids to minimize gastrointestinal irritation. * Instruct patients to take oral potassium chloride with meals or immediately after eating to reduce stomach upset. * Do not crush or chew extended-release formulations unless specifically instructed. * Rapid intravenous administration of potassium chloride is dangerous and can be fatal. It must be administered slowly and with continuous cardiac monitoring. * When titrating IV potassium, have emergency resuscitation equipment readily available. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for clinical judgment or professional medical advice. Always consult the most current prescribing information and relevant literature for complete details before making any treatment decisions. Dosing and recommendations can vary based on individual patient factors, clinical context, and institutional protocols.